🇺🇸 FDA

Intelligence · Patent portfolio

Takeda Patents

Full USPTO pharma patent portfolio for Takeda — grant dates, expiration, and drug cross-links.

Patents
1,436
Expiring ≤24m
81

Quick answer

Takeda has 1,436 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 81 expire within 24 months — use filters for patent-cliff planning.

Page 5 of 30

  1. US 11427605

    Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl) phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] phenyl} pyrimidine-2,4-diamine

    Expires Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11414496

    Anti-CD38 binding domains

    Expires Mon Aug 11 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11407748

    Substituted pyrido[1,2-a]pyrimidines and pyrazino[1,2-a]pyrimidines for enhancing AMPA receptor function

    Expires Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11407984

    Methods for purification of arysulfatase A

    Expires Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11406710

    Constrained conditionally activated binding proteins

    Expires Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11401346

    Nucleic acids encoding plasma kallikrein binding proteins

    Expires Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11390687

    Bispecific antibodies against plasma kallikrein and Factor XII

    Expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11389533

    Method of treating inflammatory bowel disease

    Expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11390634

    Fused heterocyclic compound

    Expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11370803

    Heteroaryl plasma kallikrein inhibitors

    Expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11372002

    Assays for determining plasma kallikrein system biomarkers

    Expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11357832

    Treatment of cognitive impairment of hunter syndrome by intrathecal delivery of iduronate-2-sulfatase

    Expires Mon Jun 09 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11352356

    Inhibitors of plasma kallikrein and uses thereof

    Expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11344610

    Prevention and reduction of blood loss

    Expires Mon May 26 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11340237

    Metabolite biomarkers for diseases associated with the contact activation system

    Expires Mon May 19 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11319286

    Heterocyclic compound and application thereof

    Expires Mon Apr 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11299533

    Purification of factor VIII subspecies

    Expires Mon Apr 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11299553

    Anti-plasma kallikrein antibodies

    Expires Mon Apr 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11292766

    Substituted piperidine compound and use thereof

    Expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11286307

    Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack

    Expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11285139

    Treatment of CNS conditions

    Expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11286282

    Methods of detection and removal of rhabdoviruses from cell lines

    Expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11279713

    Heterocyclic compound and use thereof

    Expires Mon Mar 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11273182

    Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in Crohn's disease

    Expires Mon Mar 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11274101

    Heterocyclic compound

    Expires Mon Mar 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 11268154

    Methods for the identification, evaluation and treatment of patients having multiple myeloma

    Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11254731

    Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A

    Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11242380

    Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use

    Expires Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11236099

    Heterocyclic compound

    Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11230545

    Heterocyclic compound

    Expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 11230541

    Heterocyclic compound

    Expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 11202776

    Treatment of gastroparesis with triazaspiro[4.5]decanone

    Expires Mon Dec 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 11197923

    Methods and compositions for live attenuated viruses

    Expires Mon Dec 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 11197916

    Lyophilized recombinant VWF formulations

    Expires Mon Dec 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 11191837

    Recombinant VWF formulations

    Expires Mon Dec 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 11191813

    Lyophilized recombinant VWF formulations

    Expires Mon Dec 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 11191818

    Use of ADAMTS13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome

    Expires Mon Dec 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 11186565

    Aromatic compound

    Expires Mon Nov 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 11185575

    Subcutaneous administration of ADAMTS13

    Expires Mon Nov 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 11179384

    Treatment of nonalcoholic fatty liver disease

    Expires Mon Nov 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 11173161

    4-oxo-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139

    Expires Mon Nov 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 11174272

    1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases

    Expires Mon Nov 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 11173208

    Liquid formulation comprising GM-CSF neutralizing compound

    Expires Mon Nov 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 11173147

    Prophylactic or therapeutic agent for delirium

    Expires Mon Nov 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 11174301

    Peptide compound

    Expires Mon Nov 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 11168083

    Inhibitors of Plasma Kallikrein and uses thereof

    Expires Mon Nov 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 11160850

    Compositions of human prothrombin and activated factor X for improving hemostasis in the treatment of bleeding disorders

    Expires Mon Oct 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 11155879

    Method of predicting effects of CDC7 inhibitor

    Expires Mon Oct 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Takeda have?

1,436 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Takeda patents expire?

81 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.